ArticleLeukemia2017

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.

E A Eksioglu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.